FBXL4 and mitochondrial disease: Here, we characterized what we believe to be novel genetic models of FBXL4–/– mitochondrial disease and evaluated the preclinical efficacy of DCA as a candidate therapy across 3 evolutionarily distinct model species, namely C. elegans, zebrafish, and human fibroblasts.